Characteristics of Cases Reviewed Individually
| Characteristics of cases reviewed individually* | n | % |
|---|---|---|
| Facilities (n = 146) | ||
| Number of facilities | 146 | |
| Hospital- or non–hospital-based scanner (n = 146) | ||
| PET scanner not hospital-based | 105 | 71.9 |
| PET scanner hospital-based | 41 | 28.1 |
| Mobile or fixed PET scanner (n = 146) | ||
| Stationary | 110 | 75.3 |
| Mobile | 36 | 24.7 |
| Cases reviewed | ||
| Number of interpreting physicians | 162 | |
| Integrated PET/CT (n = 178) | ||
| PET/CT | 149 | 83.7 |
| PET | 29 | 16.3 |
| Indication (n = 178) | ||
| Diagnosis | 41 | 23.0 |
| Initial staging | 37 | 20.8 |
| Monitoring treatment response | 28 | 15.7 |
| Restaging | 32 | 18.0 |
| Suspected recurrence | 40 | 22.5 |
| Location of cancer (n = 178) | ||
| Pancreas | 19 | 10.7 |
| Unknown primary | 17 | 9.6 |
| Stomach | 16 | 9.0 |
| Bladder | 15 | 8.4 |
| Ovary and uterine adnexa | 13 | 7.3 |
| Kidney and other urinary tract | 11 | 6.2 |
| Prostate | 11 | 6.2 |
| Liver and intrahepatic bile ducts | 7 | 3.9 |
| Lung, non–small cell | 5 | 2.8 |
| Lung, small cell | 5 | 2.8 |
| Other cancer | 59 | 33.1 |
| Cancer confirmation (n = 178) | ||
| Pathologically proven | 138 | 77.5 |
| Clinically suspected | 23 | 12.9 |
| Unknown primary cancer | 17 | 9.6 |
| Summary stage (n = 178) | ||
| No evidence of disease | 17 | 9.5 |
| Localized only | 27 | 15.2 |
| Regional by direct extension, lymph node | 27 | 15.2 |
| Metastatic with a single suspected site | 24 | 13.5 |
| Metastatic with multiple suspected sites | 41 | 23.0 |
| Unknown or uncertain | 42 | 23.6 |
| Pre-PET management plan (n = 178) | ||
| Observation | 17 | 9.5 |
| Additional imaging | 71 | 39.9 |
| Tissue biopsy | 23 | 12.9 |
| Curative treatment | 35 | 19.7 |
| Palliative treatment | 32 | 18.0 |
↵* Does not include cases read by all reviewers.